Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Sunday, April 21, 2024 | Back issues
Courthouse News Service Courthouse News Service


MINNEAPOLIS - Shareholders claim in a federal derivative complaint that Medtronic paid $40 million to settle complaints of pushing its Infuse product for off-label uses, but kept paying doctors to promote its off-label use, and propped up its share price through false and misleading statements.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.